FHA
AMRX icon

Flagship Harbor Advisors’s Amneal Pharmaceuticals AMRX Stock Holding History

Flagship Harbor Advisors’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-25
Closed -$315 – 793
2025
Q4 		$315 Buy
+25
New +$286 ﹤0.01% 2112
2018
Q4 		– Sell
-551
Closed -$12K – 1832
2018
Q3 		$12K Hold
551
– – ﹤0.01% 1315
2018
Q2 		$9K Buy
+551
New +$9.67K ﹤0.01% 1404

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Flagship Harbor Advisors's AMRX Position: Q1 2026 in Review

Flagship Harbor Advisors sold out of Amneal Pharmaceuticals (AMRX) in Q1 2026, closing a stake of 25 shares — an estimated $315 sold.

Flagship Harbor Advisors first reported a position in AMRX in Q2 2018 and held it in 3 quarters. The position peaked at $12K in Q3 2018. 317 funds tracked by Wall St. Rank hold AMRX as of Q1 2026.

  • Flagship Harbor Advisors reported no remaining Amneal Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Flagship Harbor Advisors sold 25 Amneal Pharmaceuticals shares in Q1 2026, an estimated $315.
  • Flagship Harbor Advisors first reported a position in Amneal Pharmaceuticals in Q2 2018 and held it in 3 quarters.
  • Flagship Harbor Advisors's Amneal Pharmaceuticals position peaked at $12K in Q3 2018.
  • 317 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2026.

Based on Flagship Harbor Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.